Tenecteplase

Alternative Names: TNKase

Tenecteplase (brand name TNKase) is now FDA-approved for the treatment of acute ischemic stroke in adults as of March 2025. It works by dissolving clots through plasminogen activation, similar to alteplase, but offers the advantage of a single IV bolus dose rather than a prolonged infusion. Clinical studies have shown it to be as effective as alteplase, with comparable safety and functional outcomes. Because of its ease of administration and rapid delivery, it is now considered a strong alternative

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

Tenecteplase

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the review, Tenecteplase appears to be an effective treatment for acute ischemic stroke, with FDA approval and advantages like a single IV bolus dose. The treatment offers outcomes comparable to alteplase, but careful patient selection and adherence to eligibility criteria are crucial to minimize the risk of intracranial hemorrhage.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
1.0
1 = Very Expensive 5 = Very Affordable

1.0

Very Expensive
Relief Speed
4.0
1 = No Relief 5 = Immediate Relief

4.0

Fast Relief
Side Effects
2.0
1 = Intolerable Effect 5 = No Effect

2.0

Severe Effect
Treatment Line
5.0
1 = Third-line or more 5 = First-line

5.0

First-line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review, Tenecteplase appears to be an effective treatment for acute ischemic stroke, with FDA approval and advantages like a single IV bolus dose. The treatment offers outcomes comparable to alteplase, but careful patient selection and adherence to eligibility criteria are crucial to minimize the risk of intracranial hemorrhage.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
1 month ago
Tenecteplase (TNKase) is a clot-busting medication for acute ischemic stroke that’s given as a single IV bolus, making it simpler than alteplase. It’s used within 4.5 hours of symptom onset—with better outcomes the earlier it’s given—and onset is usually based on when the patient was last seen normal. In the ED, we always get a head CT first to rule out bleeding before giving it. I’m careful to confirm patients meet all criteria, since the main risk is intracranial hemorrhage. When used appropriately, it provides outcomes comparable to alteplase with easier administration.
#VeryExpensive #FastRelief #SevereEffect #First-line #Rescue/EmergencyUse
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All